☆ 3.8 Review

Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview

CARDIOLOGY AND THERAPY (2022)

Related references

Note: Only part of the references are listed.

Review Nutrition & Dietetics

Vitamin D can be effective on the prevention of COVID-19 complications: A narrative review on molecular aspects

Amir-Abbas Shiravi et al.

Summary: This study discusses the potential effects of vitamin D on COVID-19 side effects, including its roles in inflammation control, immune modulation, oxidative stress reduction, and prevention of multi-organ failure. Supplementation of vitamin D is suggested for individuals who are deficient or at higher risk of severe effects of COVID-19 to mitigate the lethal side effects of the infection.

INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19

Javier Bautista García et al.

Revista española de cardiología (English ed.) (2021)

Add to Collection

Article

Myocarditis following COVID-19 vaccination

Elisabeth Albert et al.

Radiology Case Reports (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Geriatrics & Gerontology

The Clinical Characteristics and Risk Factors of Severe COVID-19

Jianhua Hu et al.

Summary: The study aimed to investigate the clinical characteristics and risk factors for severe cases of COVID-19 compared to non-severe patients. Male, elderly, and obese individuals, as well as those with comorbidities like hypertension, diabetes, and cardiovascular disease, were more likely to develop severe cases. Abnormalities in blood tests and laboratory findings, such as elevated CRP and reduced lymphocyte count, were key markers for severity.

GERONTOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

Guy Witberg et al.

Summary: Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

D. Mevorach et al.

Summary: The incidence of myocarditis increased after receiving the BNT162b2 vaccine in Israel, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Letter Pharmacology & Pharmacy

COVID-19 Vaccine-Associated Takotsubo Cardiomyopathy

Chinmay Jani et al.

AMERICAN JOURNAL OF THERAPEUTICS (2021)

Add to Collection

Article Immunology

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination-A report of two UK cases

Puja R. Mehta et al.

Summary: Recent reports have highlighted rare cases of CVST and thrombocytopenia following Vaxzevria vaccination. An immunological mechanism similar to HIT, but without prior heparin exposure, is suspected. Management of such cases involves PF4 antibody testing and treatment similar to HIT.

BRAIN BEHAVIOR AND IMMUNITY (2021)

Add to Collection

Article Infectious Diseases

Taquicardia como efecto adverso no descrito en la vacuna Comirnaty© (vacuna COVID-19 mRNA BNT162b2 de Pfizer-BioNTech): descripción de 3 casos con antecedentes de SARS-CoV-2

M. Teresa Marco García et al.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Acute Coronary Tree Thrombosis After Vaccination for COVID-19

Mateusz Tajstra et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2021)

Add to Collection

Article Emergency Medicine

Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine

Ibrahim Halil Ozdemir et al.

Summary: This case report presents a rare occurrence of Kounis syndrome following inactivated coronavirus vaccine administration in a 41-year-old woman. The patient developed symptoms of flushing, palpitation, dyspnea, and chest pain after vaccination, with ECG changes and elevated Troponin-I levels. Coronary angiography showed no signs of coronary atherosclerosis. This case highlights the importance of monitoring and awareness of potential allergic reactions, such as Kounis syndrome, following COVID-19 vaccination.

JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

Jerald Sadoff et al.

Summary: The manufacturer responds to recent reports of thrombosis and severe thrombocytopenia in recipients of the Ad26.COV2.S vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Covid-19 vaccine-induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma

Aashish Gupta et al.

PROGRESS IN CARDIOVASCULAR DISEASES (2021)

Add to Collection

Review Hematology

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors

Philipp von Hundelshausen et al.

Summary: Rare thromboembolic incidents following COVID-19 vaccination have led to temporary suspensions. A pathomechanism involving platelet-activating antibodies has been identified, with proposed treatments including high-dose IV immunoglobulin G and Btk inhibitors. This emergency repurposing of approved drugs in COVID-19 may provide a safe option for treating VITT.

THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

News Item Medicine, General & Internal

AstraZeneca vaccine: Blood clots are extremely rare and benefits outweigh risks, regulators conclude

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Immunology

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

Abdulla Watad et al.

Summary: Although temporally-associated with SARS-CoV-2 vaccination, new-onset or flare of immune-mediated diseases (IMDs) appear rare. Most cases are of moderate severity and responsive to therapy, although some severe flares occurred.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination

Phillip Crane et al.

Summary: Community vaccination is the primary strategy to control the global COVID-19 pandemic, but potential vaccine-related adverse events should be carefully considered.

BMJ CASE REPORTS (2021)

Add to Collection

Review Medicine, General & Internal

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later

Fabio Angeli et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine

Martina Zappa et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Letter Peripheral Vascular Disease

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Sylvain Meylan et al.

HYPERTENSION (2021)

Add to Collection

Letter Medicine, General & Internal

Myocarditis and Pericarditis After Vaccination for COVID-19

George A. Diaz et al.

Summary: This study compares the incidence of myocarditis and pericarditis in emergency department or inpatient hospital encounters before and during the period of COVID-19 vaccination availability in a large US health care system.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Considerations in boosting COVID-19 vaccine immune responses

Philip R. Krause et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Noam Barda et al.

Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Jay Montgomery et al.

Summary: This study investigated cases of myocarditis occurring in male patients within the US Military Health System after receiving mRNA COVID-19 vaccines between January and April 2021. A total of 23 male patients presented with acute chest pain within 4 days post-vaccination, with elevated troponin levels and findings consistent with myocarditis on imaging. The number of cases observed was higher than expected after a second dose of the vaccine among male military members.

JAMA CARDIOLOGY (2021)

Add to Collection

Letter Endocrinology & Metabolism

Myocardial infarction after COVID-19 vaccination-casual or causal?

Subhankar Chatterjee et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

Add to Collection

Article Immunology

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study

Xiao-Ning Li et al.

Summary: The two-dose inactivated SARS-CoV-2 vaccine showed an effectiveness of 59.0% to 70.2% against the Delta variant, with higher efficacy among participants aged 40-59 years and in females compared to males in preventing COVID-19 and moderate diseases.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ventricular Arrhythmias in Myocarditis Characterization and Relationships With Myocardial Inflammation

Giovanni Peretto et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Elissa Driggin et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Hematology

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy

Corrado Lodigiani et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Psychology, Developmental

Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System

Jorge Arana et al.

JOURNAL OF ADOLESCENT HEALTH (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Autoimmune Basis for Postural Tachycardia Syndrome

Hongliang Li et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Altered Systemic Hemodynamic and Baroreflex Response to Angiotensin II in Postural Tachycardia Syndrome

Hossam I. Mustafa et al.

CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2012)

Add to Collection

Review Cardiac & Cardiovascular Systems

Kounis syndrome: a new twist on an old disease

Nicholas G. Kounis et al.

FUTURE CARDIOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.